Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study
Kenshi Suzuki, Atsushi Shinagawa, Toshiki Uchida, Masafumi Taniwaki, Hirokazu Hirata, Kenichi Ishizawa, Kosei Matsue, Yoshiaki Ogawa, Takayuki Shimizu, Maki Otsuka, Morio Matsumoto, Shinsuke Iida, Yasuhito Terui, Itaru Matsumura, Takashi Ikeda, Naoki Takezako, Yumi Ogaki, Shuichi Midorikawa, Vanessa Houck, Annette Ervin-Haynes and Takaaki Chou
Article first published online: 30 MAR 2016 | DOI: 10.1111/cas.12916
The FIRST trial (MM-020) demonstrated that lenalidomide plus low-dose dexamethasone (Rd) reduced risk of multiple myeloma (MM) disease progression or death; however, no Japanese patients were included in the study. MM-025 evaluated the efficacy and safety of continuous Rd treatment in 26 Japanese patients with newly diagnosed MM (NDMM). The study results support the use of continuous Rd treatment in Japanese patients with NDMM.